Dragon Pharmaceutical Inc.
OTC Bulletin Board : DRUG
TSX : DDD

Dragon Pharmaceutical Inc.

July 07, 2009 16:00 ET

Dragon Pharma Releases Inaugural Issue of Dragon Pharma Review

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 7, 2009) - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company") (TSX:DDD)(OTCBB:DRUG)(BBSE:DRP), a leading international pharmaceutical company, today announced the release of the first edition of Dragon Pharma Review, the official newsletter of Dragon Pharma.

The purpose of this newsletter is two-fold - to provide insights from senior management on the Company's operations, and to offer perspective on key developments affecting its industry. The Company will use the newsletter from time to time to offer its views on government policy and market developments that affect the Chinese health and pharmaceutical industry more broadly. This inaugural issue provides a brief review of China's new health care policy and its impact on Dragon Pharma, together with health policy-related news developments.

The newsletter can be found on Dragon Pharma's website at www.dragonpharma.com.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including 7-ACA, a key intermediate to produce cephalosporin antibiotics, Clavulanic Acid, and formulated cephalosporin antibiotic drugs. Dragon is the third largest 7-ACA producer and the first manufacturer and market leader of Clavulanic Acid products in China. Dragon utilizes its nationwide sales distribution network, close customer relationships, understanding of local markets and customer needs and low cost structure to outperform its international and domestic peers. With an annual capacity of 780 tons, Dragon is the largest exporter of 7-ACA in China. To learn more about Dragon Pharmaceutical Inc., please visit www.dragonpharma.com.

Safe Harbor Statement

This press release contains forward looking statements, including but not limited to, that the Company will continue to experience growth in sales of its antibiotic products, including growth that may be attributed to adoption of the Chinese medical reform plan, that it will continue to be able to improve its production technology and efficiency, that it will continue to achieve continuous growth in business and profitability in the near future. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statements. Readers should not place undue reliance on forward looking statements, which only reflect the views of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports filed with the Securities and Exchange Commission.

Contact Information

  • Dragon Pharmaceutical Inc.
    Maggie Deng
    Chief Operating Officer
    +1(604)-669-8817 or North America Toll Free: 1-877-388-3784
    or
    Dragon Pharmaceutical Inc.
    Karen Huang
    Manager, Business Research & Development
    +1(604)-669-8817 or North America Toll Free: 1-877-388-3784
    irdragon@dragonpharma.com
    www.dragonpharma.com
    or
    Christensen Investor Relations
    Kathy Li
    +1(480) 614 3036
    kli@christensenir.com